Journal of Hepato-Biliary-Pancreatic Surgery

, Volume 15, Issue 5, pp 468–472

Adjuvant treatments for resectable pancreatic cancer

  • Hideki Ueno
  • Tomoo Kosuge
Topics

DOI: 10.1007/s00534-008-1357-3

Cite this article as:
Ueno, H. & Kosuge, T. J Hepatobiliary Pancreat Surg (2008) 15: 468. doi:10.1007/s00534-008-1357-3

Abstract

Pancreatic cancer remains one of the most challenging malignancies to treat successfully. The majority of patients present with unresectable advanced-stage cancer, and only 20% of patients can undergo resection. Even if surgical resection is performed, the recurrence rate is high and the survival rate after surgery is poor. Therefore, effective adjuvant therapy is needed to improve the prognosis of patients with pancreatic cancer. Until now, no universally accepted standard adjuvant therapy for this disease has been available: chemoradiotherapy followed by chemotherapy is considered the optimal therapy in the United States, while chemotherapy alone is the current standard in Europe. However, recent randomized controlled trials (RTOG [Radiation Therapy Oncology Group] 9704; CONKO [Charité Onkologie]-001; and a Japanese study) have suggested a benefit of adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer. This article will review the clinical trials of adjuvant therapy for this disease, including the results of recent trials.

Key words

Pancreatic cancer Adjuvant therapy Chemoradiotherapy Chemotherapy 

Copyright information

© Springer Japan 2008

Authors and Affiliations

  • Hideki Ueno
    • 1
  • Tomoo Kosuge
    • 2
  1. 1.Hepatobiliary and Pancreatic Oncology DivisionNational Cancer Center HospitalTokyoJapan
  2. 2.Hepatobiliary and Pancreatic Surgery DivisionNational Cancer Center HospitalTokyoJapan

Personalised recommendations